On the other hand, shH19 combined with Gefitinib treatment significantly increased the expression levels of PTEN and PDCD4, while decreased the expression levels of NFIB when compared with shH19 alone treatment, which suggested that Gefitinib partially inhibited PTEN signalling pathway in lung cancer in vivo. The gene discussed is NFIB; the disease is lung carcinoma.